NovoRapid® FlexPen® (NovoRapid® FlexPen®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceInsulin aspartInsulin aspart
Similar drugsTo uncover
  • NovoRapid® Penfill®
    solution PC in / in 
    Novo Nordisk A / S     Denmark
  • NovoRapid® FlexPen®
    solution in / in PC 
    Novo Nordisk A / S     Denmark
    • Dosage form: & nbspsolution for subcutaneous and intravenous administration
    Composition:

    In 1 ml of the drug contains:

    active substance: insulin aspart 100 ED (3.5 mg);

    Excipients: glycerol 16 mg, phenol 1.5 mg, metacresol 1.72 mg, zinc chloride 19.6 μg, sodium chloride 0.58 mg, sodium hydrogen phosphate dihydrate 1.25 mg, sodium hydroxide 2 M about 2.2 mg, acid hydrochloric 2 M about 1.7 mg, water for injection up to 1 ml.

    One syringe pen contains 3 ml of a solution equivalent to 300 units.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:hypoglycemic agent - short-acting insulin analog
    ATX: & nbsp

    A.10.A.B.05   Insulin aspart

    Pharmacodynamics:

    Insulin aspart - an analog of human short-acting insulin, produced by the method of biotechnology of recombinant DNA using a strain Saccharomyces cerevisiae, in which the amino acid proline at position B28 is substituted for aspartic acid.

    Interacts with a specific receptor of the external cytoplasmic cell membrane and forms an insulin-receptor complex that stimulates intracellular processes,synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthase, etc.). Reduction of blood glucose is due to increased intracellular transport, increased digestion, stimulation of lipogenesis, glycogenogenesis, a decrease in the rate of production of glucose by the liver, etc.

    Substitution of amino acid proline in position B28 for aspartic acid in insulin aspart reduces the tendency of molecules to form hexamers, which is observed in a solution of normal insulin. Concerning insulin aspart much more quickly absorbed from the subcutaneous fat and starts to act faster than soluble human insulin. Insulin aspart stronger reduces blood glucose in the first 4 hours after ingestion than soluble human insulin. The duration of action of insulin aspart after subcutaneous administration is shorter than that of soluble human insulin.

    After subcutaneous administration, the drug starts within 10-20 minutes after administration. The maximum effect is observed 1-3 hours after the injection. The duration of the drug is 3-5 hours.Clinical studies involving patients with type 1 diabetes mellitus demonstrated a reduced risk of nocturnal hypoglycemia with insulin aspart compared to soluble human insulin. The risk of diurnal hypoglycemia did not increase reliably.

    Insulin aspart is an equipotential soluble human insulin based on the molarity index.

    Adults. Clinical trials involving patients with type 1 diabetes mellitus exhibit a lower postprandial blood glucose concentration when insulin is administered aspart compared to soluble human insulin.

    Elderly. A randomized, double-blind, cross-over study of the pharmacokinetics and pharmacodynamics (PK / PD) of insulin aspart and soluble human insulin in elderly patients with type 2 diabetes (19 patients aged 65-83 years, mean age 70 years) was performed. The relative differences in the pharmacodynamic properties between insulin aspart and soluble human insulin in elderly patients were similar to those in healthy volunteers and in younger patients with diabetes mellitus.

    Children and teens. The use of insulin aspart in children showed similar results from long-term glycemic control when compared to soluble human insulin.

    A clinical study using soluble human insulin before meals and insulin aspart after meals was performed in small children (26 patients aged 2 to 6 years), and a single-dose PC / PD study was performed in children (6 -12 years) and adolescents (13-17 years). The pharmacodynamic profile of insulin aspart in children was similar to that of adult patients.

    Pregnancy. Clinical studies of the relative safety and efficacy of insulin aspart and human insulin in the treatment of pregnant women with type 1 diabetes mellitus (322 examined pregnant women, 157 received insulin aspart, 165 - human insulin) did not reveal any negative effects of insulin aspart during pregnancy or fetus / newborn health.

    Additional clinical studies in 27 women with gestational diabetes who receive insulin aspart and human insulin (insulin aspart received 14 women, human insulin - 13) testify to the comparability of safety profiles, along with a significant improvement in glucose control after meals in the treatment of insulin aspart.

    Pharmacokinetics:

    After subcutaneous injection of insulin aspart the time to reach the maximum concentration (tmax) in blood plasma is on average 2 times less than after the administration of soluble human insulin. The maximum concentration in the blood plasma (CmOh) on the average is 492 ± 256 pmol / l and is achieved 40 minutes after subcutaneous administration of a dose of 0.15 U / kg of body weight to patients with type 1 diabetes mellitus. The concentration of insulin returns to the baseline level 4-6 hours after the administration of the drug. The absorption rate is somewhat lower in patients with type 2 diabetes, which results in a lower maximum concentration (352 ± 240 pmol / L) and a later tmax (60 minutes). Inside, the individual variability for tmax is significantly lower when using insulin aspart as compared to soluble human insulin, whereas the indicated variability in CmOh for insulin aspart more.

    Pharmacokinetics in children (6-12 years) and adolescents (13-17 years) with type 1 diabetes mellitus. Absorption of insulin aspart is rapid in both age groups with tmax, similar to that of adults. However, there are differences CmOh in two age groups, which emphasizes the importance of individual dosing of the drug.

    The elderly. The relative differences in pharmacokinetics between insulin aspart and soluble human insulin in elderly patients (65-83 years old, mean age 70 years) type 2 diabetes mellitus were similar to those in healthy volunteers and in younger patients with diabetes mellitus. In elderly patients there was a decrease in the rate of absorption, which led to a slowing down of tmax (82 (variability: 60-120) minutes), whereas CmOh was the same as that observed in younger patients with type 2 diabetes and slightly less than in patients with type 1 diabetes.

    Lack of liver function. A study was conducted pharmacokinetics with the introduction of a single dose of insulin aspart in 24 patients whose liver function is in the range from normal to severe form of disorder. In persons with impaired liver function, the rate of absorption of insulin aspart was reduced and more unstable, resulting in a delay of tmax with approximately 50 minutes in individuals with normal liver function to about 85 minutes in individuals with impaired liver function of moderate to severe severity. The area under the concentration-time curve, the maximum concentration in the plasma and the overall clearance of the drug (AUC, Cmax and CL / F) were similar in individuals with reduced and normal liver function.

    Lack of kidney function. A study was conducted pharmacokinetics of insulin aspart in 18 patients whose renal function ranged from normal to severe form of disorder. There was no clear effect of creatinine clearance on AUC, Cmax, tmax insulin aspart. Data were limited to indicators for people with impaired renal function of medium and severe form. Persons with renal insufficiency requiring dialysis were not included in the study.

    Preclinical safety data

    Pre-clinical studies have not identified any hazard to humans, based on data from generally accepted pharmacological safety studies, re-use toxicity, genotoxicity, and reproductive toxicity.

    In the tests in vitro, including binding to insulin receptors and insulin-like growth factor-1, as well as the effect on cell growth,The nature of the behavior of insulin aspart is very similar to that of human insulin. The results of the studies also showed that the dissociation of the binding of insulin aspart with the insulin receptor is equivalent to that of human insulin.

    Indications:

    Diabetes mellitus in adults, adolescents and children older than 2 years.

    Contraindications:

    Increased individual sensitivity to insulin aspart or any of the components of the drug.

    It is not recommended to use the drug NovoRapid® FlexPen® in children under 2 years of age, clinical studies in children younger than 2 years have not been conducted.

    Pregnancy and lactation:

    NovoRapid® FlexPen® can be administered during pregnancy.

    The data of two randomized controlled clinical trials (157 + 14 examined pregnant women) did not reveal any adverse effects of insulin aspart during pregnancy or fetus / newborn health compared to human insulin (see section "Pharmacological properties"). It is recommended to carefully monitor blood glucose levels and monitor pregnant women with diabetes mellitus (type 1 diabetes, type 2 diabetes or gestational diabetes), throughout pregnancy and during the period of possible pregnancy.The need for insulin, as a rule, decreases in the first trimester and gradually rises in the II and III trimesters of pregnancy. Shortly after birth, the need for insulin quickly returns to the level that was before pregnancy.

    In the period of breastfeeding NovoRapid® FlexPen® can be used, since The introduction of insulin to a woman during lactation does not pose a threat to the child. However, it may be necessary to adjust the dose of the drug.

    Dosing and Administration:

    NovoRapid® FlexPen® is a quick-acting insulin analog.

    The dose of NovoRapid® FlexPen® is determined by the physician individually according to the patient's needs. Usually the drug is used in combination with insulin preparations of medium duration or long-term action, which are administered at least 1 time per day. To achieve optimal glycemic control, it is recommended to regularly measure the concentration of glucose in the blood and adjust the dose of insulin. Usually, the individual daily requirement for insulin in adults and children is 0.5 to 1 unit / kg of body weight. When the drug is administered before meals,the need for insulin can be provided with NovoRapid® FlexPlex® by 50-70%, the remaining need for insulin is provided by prolonged-action insulin.

    Increasing the physical activity of the patient, changing the habitual diet or co-morbidities can lead to the need for dose adjustment. NovoRapid® FlexPan® has a faster start and a shorter duration of action than soluble human insulin. Due to the quicker onset of action, NovoRapid® FlexPen® should, as a rule, immediately before meals, if necessary, can be administered soon after meals.

    Due to the shorter duration of action compared to human insulin, the risk of developing nocturnal hypoglycemia in patients receiving NovoRapid® FlexPan® is lower.

    Special patient groups

    As with the use of other insulins, in elderly patients and patients with renal or hepatic insufficiency, it is necessary to more closely monitor the concentration of glucose in the blood and adjust the dose of insulin aspart individually.

    Children and teens

    To use NovoRapid® FlexPen® instead of soluble human insulin in children is preferable when a rapid onset of action of the drug is necessary, for example, when it is difficult for a child to observe the necessary time interval between injection and ingestion.

    Translation from other insulin preparations

    When transferring a patient from other insulin preparations to NovoRapid® FlexPen®, a dose adjustment of NovoRapid® FlexPen® and basal insulin may be required.

    NovoRapid® FlexPen® is injected subcutaneously into the anterior abdominal wall, thigh, shoulder, deltoid or gluteal region. Injection sites within the same body site should be changed regularly to reduce the risk of developing lipodystrophy. As with all insulin preparations, subcutaneous injection into the anterior abdominal wall provides faster absorption than when injected elsewhere. The duration of action depends on the dose, place of administration, intensity of blood flow, temperature and level of physical activity. Nevertheless, a more rapid onset of action than soluble human insulin persists regardless of the localization of the injection site.

    NovoRapid® can be used for long-term subcutaneous insulin infusions (CPII) in insulin pumps designed for insulin infusions. PPII should be made in the anterior abdominal wall. Place infusions should be periodically changed.

    When using an insulin pump for infusions NovoRapid® should not be mixed with other types of insulin. Patients using FPII should be fully trained in the use of the pump, the appropriate reservoir and the piping system for the pump. The infusion set (tube and catheter) should be replaced in accordance with the user manual that accompanies the infusion set.

    Patients receiving NovoRapid® with PSI should have additional insulin available in case of breakage of the infusion system.

    Intravenous administration

    If necessary, NovoRapid® may be administered intravenously, but only by qualified medical personnel.

    For intravenous administration, infusion systems with NovoRapid ® 100 U / ml preparation with concentrations from 0.05 U / ml to 1 U / ml of insulin aspart in 0.9% sodium chloride solution are used; 5% dextrose solution or 10% dextrose solution containing 40 mmol / L potassium chloride, using polypropylene infusion containers.These solutions are stable at room temperature for 24 hours. Despite stability for some time, a certain amount of insulin is initially absorbed by the material of the infusion system. During insulin infusions, it is necessary to constantly monitor the concentration of blood glucose.

    Side effects:

    Adverse reactions observed in patients using the drug NovoRapid® FlexPen® are mainly due to the pharmacological effect of insulin.

    The most common adverse reaction is hypoglycemia. The incidence of side effects varies depending on the patient population, dosage regimen and glycemic control (see section below).

    At the initial stage of insulin therapy, refractive disorders, edema and reactions at the injection site (pain, redness, urticaria, inflammation, bruising, swelling and itching at the injection site) may occur. These symptoms are usually transient. Rapid improvement in glycemic control can lead to a state of "acute pain neuropathy," which is usually reversible.

    Intensification insulin therapy with a dramatic improvement in the control of carbohydrate metabolism may lead to a temporary deterioration in the state of diabetic retinopathy, while a prolonged improvement in glycemic control reduces the risk of progression of diabetic retinopathy.

    The list of adverse reactions is presented in the table.

    All of the adverse reactions presented below, based on data from clinical trials, are grouped according to the frequency of development according to MedDRA and organ systems. The incidence of adverse reactions is defined as: very often (≥ 1/10); often (≥ 1/100 to <1/10); infrequently (≥1 / 1,000 to <1/100); rarely (≥1 / 10,000 to <1 / 1,000), very rarely (<1 / 10,000) and unknown (impossible to estimate based on available data).

    Immune system disorders

    Infrequent - hives, skin rashes, skin rashes

    Very rarely - anaphylactic reactions *

    Disorders from the metabolism and nutrition

    Very often - hypoglycemia *

    Disturbances from the nervous system

    Rarely - peripheral neuropathy ("acute pain neuropathy")

    Disturbances on the part of the organ of sight

    Infrequent refractive disorders

    Infrequently - diabetic retinopathy

    Disturbances from the skin and subcutaneous tissues

    Infrequent - lipodystrophy *

    General disorders and disorders at the site of administration

    Infrequently - reactions in places of administration

    Infrequent - swelling

    *Cm. "Description of individual adverse reactions"

    Description of individual adverse reactions

    Anaphylactic reactions

    Very rare reactions of generalized hypersensitivity were noted (including generalized skin rash, itching, increased sweating, gastrointestinal disorders, angioedema, difficulty breathing, heart palpitations, decrease in blood pressure), which are potentially life-threatening.

    Hypoglycaemia

    Hypoglycemia is the most common side effect. It can develop if the dose of insulin is too high in relation to the need for insulin. Severe hypoglycemia can lead to loss of consciousness and / or convulsions, temporary or irreversible impairment of brain function up to a lethal outcome. Symptoms of hypoglycemia, as a rule, develop suddenly. These may include cold sweats, pale skin, increased fatigue, nervousness or tremor, anxiety, unusual fatigue or weakness, impaired orientation, decreased concentration,drowsiness, a marked feeling of hunger, impaired vision, headache, nausea and heart palpitations. Clinical studies have shown that the incidence of hypoglycemia varies depending on the patient population, dosing regimen, and glycemic control. Clinical studies showed no difference in the overall incidence of episodes of hypoglycemia between patients receiving insulin aspart therapy and patients using human insulin preparations.

    Lipodystrophy

    There were reports of infrequent cases of development of lipodystrophy. Lipodystrophy can develop at the site of injection.

    Overdose:

    A certain dose required for an insulin overdose has not been established, but hypoglycemia can develop gradually if too high doses are administered in relation to the patient's need.

    - Light hypoglycemia the patient can eliminate himself by taking glucose or sugar-containing foods. Therefore, patients with diabetes are encouraged to constantly carry with them sugar-containing foods.

    - In case of severe hypoglycemia, when the patient is unconscious, should be administered from 0.5 mg to 1 mg glucagon intramuscularly or subcutaneously (can be administered by a trained person) or intravenously glucose solution (dextrose) (may be administered only by a medical professional). It is also necessary to introduce intravenous dextrose in the case if the patient does not regain consciousness 10-15 minutes after the introduction of glucagon. After restoration of consciousness, the patient is recommended to take a carbohydrate-rich food to prevent the recurrence of hypoglycemia.

    Interaction:

    There are a number of drugs that affect the need for insulin.

    Hypoglycemic action of insulin increases oral hypoglycemic drugs, monoamine oxidase inhibitors, angiotensin converting enzyme inhibitors, inhibitors carbonic anhydrases, nonselective beta-blockers, bromocriptine, sulfonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations, salicylates.

    Hypoglycemic action of insulin weakens oral contraceptives, glucocorticosteroids, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, somatropin, danazol, clonidine, blockers of "slow" calcium channels, diazoxide, morphine, phenytoin, nicotine.

    Beta-blockers can mask symptoms of hypoglycemia.

    Octreotide / lanreotide can both increase and decrease the need for insulin.

    Alcohol can both enhance and reduce the hypoglycemic effect of insulin.

    Incompatibility

    Some drugs, for example, containing thiol or sulphite groups, when added to NovoRapid ® FlexPen ® can cause destruction of insulin aspart. The drug NovoRapid® FlexPen® should not be mixed with other drugs. The exception is isophane-insulin and solutions for infusions, described in the section "Method of administration and dose".

    Special instructions:

    Before a long trip associated with the change of time zones, the patient should consult with his attending physician, as changing the time zone means that the patient must take food and inject insulin at another time.

    Hyperglycaemia

    Insufficient dose of the drug or discontinuation of treatment, especially in type 1 diabetes, can lead to the development of hyperglycemia and diabetic ketoacidosis.Typically, the symptoms of hyperglycemia appear gradually, within a few hours or days. Symptoms of hyperglycemia include nausea, vomiting, drowsiness, redness and dryness of the skin, dry mouth, increased urine output, thirst and loss of appetite, and the appearance of an odor of acetone in the exhaled air. Without proper treatment, hyperglycemia can lead to death.

    Hypoglycaemia

    Skipping meals, unplanned increased physical activity or too high a dose of insulin in relation to the patient's need may lead to hypoglycemia.

    After compensating for carbohydrate metabolism, for example, with intensified insulin therapy, the symptoms typical for them, precursors of hypoglycemia, can change in patients, which patients should be informed about.

    Common symptoms-precursors can disappear with prolonged course of diabetes.

    A consequence of the pharmacodynamic characteristics of short-acting insulin analogs is that the development of hypoglycemia in their use can begin earlier than when using soluble human insulin.

    Since NovoRapid® FlexPen® should be used in direct connection with food intake, the high rate of onset of the drug effect should be considered in the treatment of patients who have comorbid diseases or who take medications that slow food intake. Concomitant diseases, especially infectious and accompanied usually increase the body's need for insulin. Correction of the dose of the drug may also be required if the patient has concomitant diseases of the kidneys, liver, adrenal, pituitary or thyroid gland disorders.

    When transferring the patient to other types of insulin, early symptoms-precursors of hypoglycemia may become less pronounced, compared with those with the previous type of insulin.

    Transfer of a patient from other insulin preparations

    Transfer of the patient to a new type of insulin or an insulin preparation of another manufacturer must be carried out under strict medical supervision. With a change in concentration, type, producer and species (human insulin, animal insulin,analog of human insulin) insulin preparations and / or manufacturing method, a dose change or an increase in injection frequency may be required compared to previously used insulin preparations. If it is necessary to adjust the dose, it can be done already at the first administration of the drug or during the first weeks or months of treatment.

    Reactions at the site of administration

    As with other insulin preparations, reactions at the injection site may develop, which is manifested by pain, redness, hives, inflammation, bruising, swelling and itching. Regular injection site changes in the same anatomical area can reduce symptoms or prevent the development of reactions. In very rare cases, it may be necessary to cancel NovoRapid® FlexPan®.

    The simultaneous use of drugs of the thiazolidinedione group and insulin preparations

    Cases of chronic heart failure in the treatment of patients with thiazolidinediones in combination with insulin preparations have been reported, especially if such patients have risk factors for developing chronic heart failure.This fact should be taken into account when appointing patients combination therapy with thiazolidinediones and insulin preparations. In the appointment of such combination therapy, it is necessary to conduct medical examinations of patients to identify signs and symptoms of chronic heart failure, increase in body weight and the presence of edema. If the symptoms of heart failure worsen in patients, treatment with thiazolidinediones should be discontinued.

    Precautions for use

    NovoRapid® FlexPlex® and needles are for personal use only. Do not refill the syringe pen cartridge. NovoRapid® FlexPan® can not be used if it has ceased to be clear and colorless, or if it has been frozen. Inform the patient of the need to discard the needle after each injection.

    NovoRapid® can be used in insulin pumps (see "Method of administration and dose"). Pipes, the inner surface of which is made of polyethylene or polyolefin, have been checked and found suitable for use in pumps.

    In emergency cases (hospitalization, failure of the insulin delivery device) NovoRapid® for administration to the patient can be extracted from FlexPen® using an insulin syringe U100.

    Instructions for patients on the use of NovoRapid® FlexPen®

    Do not use NovoRapid® FlexPlex®:

    - In case of allergy (hypersensitivity) to insulin aspart or any other component of NovoRapid®.

    - If you have hypoglycemia (low blood sugar).

    - If FlexPen® is dropped, or it is damaged or crushed.

    - If the storage conditions of the preparation have been violated or he was is frozen.

    - If insulin has ceased to be transparent and colorless.

    Before using NovoRapid® FlexPlex®:

    - Check the label to make sure, that the correct type of insulin is selected.

    - Always use a new needle for each injection to prevent infection.

    - NovoRapid® FlexPlex® and needles are for personal use only.

    Mode of application

    NovoRapid® is intended for subcutaneous injections or prolonged infusions in the insulin pump system (PPII). NovoRapid® can also be administered intravenously under the strict supervision of a physician.Never administer an insulin drug intramuscularly.

    Each time, change the injection site within the anatomical area. it will help reduce the risk of formation of seals and ulcers at the site of administration. It is best to inject the drug into the front abdominal wall, shoulder or front surface of the thigh. Insulin will act faster if it is injected into the anterior abdominal wall. Regularly measure the concentration of glucose in the blood.

    How to use NovoRapid® FlexPen®

    Carefully read the attached Instruction for Patients on NovoRapid® FlexPen®.

    Use your syringe pen in strict accordance with this instruction.

    Instructions for patients on the use of NovoRapid® FlexPen®

    Read these instructions carefully before using NovoRapid® FlexPlex®.

    NovoRapid® FlexPen® is a unique insulin syringe pen with a dispenser and color coding. The injected dose of insulin, ranging from 1 to 60 units, can vary in steps of 1 unit. NovoRapid® FlexPlex® is designed for use with NovoFine® and NovoTvist® disposable needles up to 8 mm in length.As a precaution, always carry a spare insulin delivery system in case you lose or damage your NovoRapid® FlexPan® (see Figures 1, 2).

    Getting Started

    Check the label to make sure that NovoRapid® FlexPan® contains the type of insulin you need.

    A. Remove the cap from the syringe pen.

    B. Remove the protective sticker from the new disposable needle. Carefully and tightly screw the needle onto NovoRapid® FlexPlex®.

    FROM. Remove the outer cap from the needle, but do not throw it away.

    D. Remove and discard the inner needle cap.

    - For each injection, use a new needle to prevent infection.

    - Be careful not to bend or damage the needle before use.

    - To avoid accidental injections, never put the inner cap back on the needle.

    Insulin intake check

    Even with the correct use of the syringe pen, a small amount of air can accumulate in the cartridge before each injection.

    To prevent the ingress of air bubbles and ensure the introduction of the correct dose of the drug:

    E. Type 2 units of the drug by turning the dose selector.

    F. Holding NovoRapid® FlexPan® with the needle up, tap the cartridge lightly with your fingertip several times to allow air bubbles to move to the top of the cartridge.

    G. While holding NovoRapid® FlexPan® with the needle up, press the start button all the way.

    The dosage selector will return to zero.

    At the end of the needle should appear a drop of insulin. If this does not happen, replace the needle and repeat the procedure, but no more than 6 times.

    If insulin does not come from the needle, this indicates that the pen syringe is faulty and is not subject to further use.

    Dose setting

    Make sure the dose selector is set to "O".

    H. Dial the number of units needed for the injection.

    The dose can be adjusted by rotating the dose selector in any direction until the correct dose is established opposite the dosing indicator. When rotating the dose selector, be careful not to accidentally press the start button to avoid dosing the insulin dose.

    It is not possible to set a dose that exceeds the number of units remaining in the cartridge.

    - You can not use a residue scale to measure the dose of insulin.

    Introduction of insulin

    Insert the needle under the skin. Use the injection technique recommended by your doctor.

    I. To do the injection, press the start button all the way until "O" appears opposite the dosing indicator. Be careful: when you inject the drug, you should only press the start button.

    When the selector is rotated, the dose will not enter the dose.

    J. When removing the needle from under the skin, hold the start button all the way down.

    After injection, leave the needle under the skin for at least 6 seconds. This will ensure the introduction of a full dose of insulin.

    C. Point the needle into the outer cap of the needle without touching the cap. When the needle goes inside, put on the cap and unscrew the needle (see pictures AK).

    Discard the needle, observing the precautionary measures, and close the syringe handle with a cap.

    - Remove the needle after each injection and never store NovoRapid® FlexPen® with the attached needle. Otherwise, it is possible to drain liquid from NovoRapid® FlexPan®, which can lead to incorrect dosage.

    - Persons caring for the patient should be careful when removing and disposing of needles to avoid the risk of accidental needle pricking.

    - Dispose of used NovoRapid® FlexPan® with the needle disconnected.

    - Needles and NovoRapid® FlexPlex® are for personal use only.

    Storage and Care

    NovoRapid® FlexPlex® is designed for effective and safe use and requires careful handling. In the event of a fall or strong mechanical impact, it is possible to damage the syringe handle and leakage of insulin. The surface of NovoRapid® FlexPen® can be cleaned with a cotton swab dipped in alcohol. Do not immerse the syringe handle in a liquid, do not wash or lubricate it, this may damage the mechanism.

    Do not refill NovoRapid® FlexPan®.

    Effect on the ability to drive transp. cf. and fur:

    The ability of patients to concentrate and respond to the reaction may be impaired during hypoglycemia, which can be dangerous in situations where these abilities are particularly necessary (for example, when driving vehicles or working with machines and mechanisms). Patients should be advised to take measures to prevent the development of hypoglycemia in the management of vehicles and work with mechanisms.This is especially important for patients with a lack or decrease in the severity of symptoms-precursors of developing hypoglycemia or suffering from frequent episodes of hypoglycemia.

    Form release / dosage:

    Solution for subcutaneous and intravenous administration, 100 units / ml.

    Packaging:

    By 3 ml of the drug in the cartridges of glass 1 of hydrolytic class with brombutyl rubber pistons sealed with bromobutyl rubber / polyisoprene discs on one side and sealed in plastic multi-dose disposable syringe-pens for multiple injections on the other.

    For 5 plastic multi-dose disposable syringe pens for multiple injections, along with instructions for use, are placed in a cardboard box.

    Storage conditions:

    Store at a temperature of 2 to 8 ° C (in the refrigerator), but not next to the freezer.

    Do not freeze.

    To protect from light, store the syringe pen with the cap on.

    NovoRapid® FlexPen® should be protected from the effects of excessive heat and light.

    Used or transported as a spare syringe-pen with the drug is not stored in the refrigerator.

    Store at a temperature not exceeding 30 ° C. Use within 4 weeks.

    Keep out of the reach of children.

    Shelf life:

    30 months.

    Do not use after the time indicated on the label of the syringe pen and package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N016171 / 01
    Date of registration:01.12.2009
    The owner of the registration certificate:Novo Nordisk A / SNovo Nordisk A / S Denmark
    Manufacturer: & nbsp
    Representation: & nbspNOVO NORDISK TOVNOVO NORDISK TOVDenmark
    Information update date: & nbsp24.10.2015
    Illustrated instructions
    Instructions
    Up